Literature DB >> 29621732

C5a receptor1 inhibition alleviates influenza virus-induced acute lung injury.

Nianping Song1, Pei Li2, Yuting Jiang2, Hong Sun3, Jing Cui3, Guangyu Zhao2, Dan Li2, Yan Guo2, Yuehong Chen2, Jimin Gao4, Shihui Sun5, Yusen Zhou6.   

Abstract

Influenza A virus is an important human pathogen that causes 3 to 5 million severe cases of influenza worldwide each year. An aberrant innate immune response, particularly hypercytokinemia, is thought to play an important role in the disease, although the pathogenesis of severe influenza virus infection remains unclear and no specific and efficacious immunotherapy is available. This study reports dysregulated complement activation in mice after infection with A/Puerto Rico/8/34 (PR8). C5aR1-deficient mice and mice treated with an anti-C5aR1 antibody were used as models to study the C5a-C5aR1 axis during acute lung injury (ALI) induced by influenza virus infection. The results showed that blocking the C5a-C5aR1 axis alleviated ALI by inhibiting endothelial cell activation and dampening the host immune response (i.e., reduced TNF-α, IL-1β, IL-6, IP-10, MCP-1, IL-12p70, and IFN-γ concentrations in plasma), particularly CTL-mediated immunopathology. Furthermore, blockade of the C5a-C5aR1 axis inhibited viral replication in lung tissue. Taken together, the results indicate that the C5a-C5aR1 axis plays an important role in the outcome of ALI induced by influenza virus infection and that regulation of complement activation, particularly the C5aR1 inhibition, is a promising intervention and adjunctive treatment.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Acute lung injury; C5aR1 inhibition; Complement; Immune response; Influenza

Mesh:

Substances:

Year:  2018        PMID: 29621732     DOI: 10.1016/j.intimp.2018.03.029

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  6 in total

Review 1.  Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants.

Authors:  William R Strohl; Zhiqiang Ku; Zhiqiang An; Stephen F Carroll; Bruce A Keyt; Lila M Strohl
Journal:  BioDrugs       Date:  2022-04-27       Impact factor: 7.744

Review 2.  New Insights into the Role of the Complement System in Human Viral Diseases.

Authors:  Ewa Ostrycharz; Beata Hukowska-Szematowicz
Journal:  Biomolecules       Date:  2022-01-28

Review 3.  Emerging roles of the complement system in host-pathogen interactions.

Authors:  Sanjaya K Sahu; Devesha H Kulkarni; Ayse N Ozanturk; Lina Ma; Hrishikesh S Kulkarni
Journal:  Trends Microbiol       Date:  2021-09-29       Impact factor: 17.079

Review 4.  In the Crosshairs: RNA Viruses OR Complement?

Authors:  Nisha Asok Kumar; Umerali Kunnakkadan; Sabu Thomas; John Bernet Johnson
Journal:  Front Immunol       Date:  2020-09-29       Impact factor: 7.561

5.  Identification of Nifurtimox and Chrysin as Anti-Influenza Virus Agents by Clinical Transcriptome Signature Reversion.

Authors:  Yijing Xin; Shubing Chen; Ke Tang; You Wu; Ying Guo
Journal:  Int J Mol Sci       Date:  2022-02-21       Impact factor: 5.923

6.  Hepatitis B Virus Core Protein Mediates the Upregulation of C5α Receptor 1 via NF-κB Pathway to Facilitate the Growth and Migration of Hepatoma Cells.

Authors:  Fanyun Kong; Yukai Tao; Dongchen Yuan; Ning Zhang; Qi Li; Tong Yu; Xiaoying Yang; Delong Kong; Xiaohui Ding; Xiangye Liu; Hongjuan You; Kuiyang Zheng; Renxian Tang
Journal:  Cancer Res Treat       Date:  2020-11-16       Impact factor: 4.679

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.